Cargando…

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

BACKGROUND: The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes of most industrialised countries and recently in two African GAVI eligible countries (Rwanda and The Gambia). However the long term effects of PCV are still unclear, as beneficial direct a...

Descripción completa

Detalles Bibliográficos
Autores principales: Melegaro, Alessia, Choi, Yoon Hong, George, Robert, Edmunds, W John, Miller, Elizabeth, Gay, Nigel J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867993/
https://www.ncbi.nlm.nih.gov/pubmed/20377886
http://dx.doi.org/10.1186/1471-2334-10-90
_version_ 1782181021888806912
author Melegaro, Alessia
Choi, Yoon Hong
George, Robert
Edmunds, W John
Miller, Elizabeth
Gay, Nigel J
author_facet Melegaro, Alessia
Choi, Yoon Hong
George, Robert
Edmunds, W John
Miller, Elizabeth
Gay, Nigel J
author_sort Melegaro, Alessia
collection PubMed
description BACKGROUND: The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes of most industrialised countries and recently in two African GAVI eligible countries (Rwanda and The Gambia). However the long term effects of PCV are still unclear, as beneficial direct and herd immunity effects might be countered by serotype replacement. METHOD: A dynamic, age-structured, compartmental model of Streptococcus pneumoniae transmission was developed to predict the potential impact of PCV7 on the incidence of invasive disease accounting for both herd immunity and serotype replacement effects. The model was parameterised using epidemiological data from England and Wales and pre and post-vaccination surveillance data from the US. RESULTS: Model projections showed that serotype replacement plays a crucial role in determining the overall effect of a PCV7 vaccination programme and could reduce, negate or outweigh its beneficial impact. However, using the estimate of the competition parameter derived from the US post-vaccination experience, an infant vaccination programme would prevent 39,000 IPD cases in the 20 years after PCV7 introduction in the UK. Adding a catch-up campaign for under 2 or under 5 year olds would provide a further reduction of 1,200 or 3,300 IPD cases respectively, mostly in the first few years of the programme. CONCLUSIONS: This analysis suggests that a PCV vaccination programme would eradicate vaccine serotypes from circulation. However, the increase in carriage of non-vaccine serotypes, and the consequent increase in invasive disease, could reduce, negate or outweigh the benefit. These results are sensitive to changes in the protective effect of the vaccine, and, most importantly, to the level of competition between vaccine and non-vaccine types. The techniques developed here can be used to assess the introduction of vaccination programmes in developing countries and provide the basis for cost-effectiveness analyses.
format Text
id pubmed-2867993
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28679932010-05-12 Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease Melegaro, Alessia Choi, Yoon Hong George, Robert Edmunds, W John Miller, Elizabeth Gay, Nigel J BMC Infect Dis Research Article BACKGROUND: The 7-valent pneumococcal conjugate vaccine has been introduced in national immunisation programmes of most industrialised countries and recently in two African GAVI eligible countries (Rwanda and The Gambia). However the long term effects of PCV are still unclear, as beneficial direct and herd immunity effects might be countered by serotype replacement. METHOD: A dynamic, age-structured, compartmental model of Streptococcus pneumoniae transmission was developed to predict the potential impact of PCV7 on the incidence of invasive disease accounting for both herd immunity and serotype replacement effects. The model was parameterised using epidemiological data from England and Wales and pre and post-vaccination surveillance data from the US. RESULTS: Model projections showed that serotype replacement plays a crucial role in determining the overall effect of a PCV7 vaccination programme and could reduce, negate or outweigh its beneficial impact. However, using the estimate of the competition parameter derived from the US post-vaccination experience, an infant vaccination programme would prevent 39,000 IPD cases in the 20 years after PCV7 introduction in the UK. Adding a catch-up campaign for under 2 or under 5 year olds would provide a further reduction of 1,200 or 3,300 IPD cases respectively, mostly in the first few years of the programme. CONCLUSIONS: This analysis suggests that a PCV vaccination programme would eradicate vaccine serotypes from circulation. However, the increase in carriage of non-vaccine serotypes, and the consequent increase in invasive disease, could reduce, negate or outweigh the benefit. These results are sensitive to changes in the protective effect of the vaccine, and, most importantly, to the level of competition between vaccine and non-vaccine types. The techniques developed here can be used to assess the introduction of vaccination programmes in developing countries and provide the basis for cost-effectiveness analyses. BioMed Central 2010-04-08 /pmc/articles/PMC2867993/ /pubmed/20377886 http://dx.doi.org/10.1186/1471-2334-10-90 Text en Copyright ©2010 Melegaro et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Melegaro, Alessia
Choi, Yoon Hong
George, Robert
Edmunds, W John
Miller, Elizabeth
Gay, Nigel J
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
title Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
title_full Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
title_fullStr Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
title_full_unstemmed Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
title_short Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
title_sort dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867993/
https://www.ncbi.nlm.nih.gov/pubmed/20377886
http://dx.doi.org/10.1186/1471-2334-10-90
work_keys_str_mv AT melegaroalessia dynamicmodelsofpneumococcalcarriageandtheimpactoftheheptavalentpneumococcalconjugatevaccineoninvasivepneumococcaldisease
AT choiyoonhong dynamicmodelsofpneumococcalcarriageandtheimpactoftheheptavalentpneumococcalconjugatevaccineoninvasivepneumococcaldisease
AT georgerobert dynamicmodelsofpneumococcalcarriageandtheimpactoftheheptavalentpneumococcalconjugatevaccineoninvasivepneumococcaldisease
AT edmundswjohn dynamicmodelsofpneumococcalcarriageandtheimpactoftheheptavalentpneumococcalconjugatevaccineoninvasivepneumococcaldisease
AT millerelizabeth dynamicmodelsofpneumococcalcarriageandtheimpactoftheheptavalentpneumococcalconjugatevaccineoninvasivepneumococcaldisease
AT gaynigelj dynamicmodelsofpneumococcalcarriageandtheimpactoftheheptavalentpneumococcalconjugatevaccineoninvasivepneumococcaldisease